Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Triple Negative Breast Cancer|Estrogen-receptor-low Breast Cancer
Interventions: DRUG: Carboplatin|DRUG: Tocilizumab
Sponsor: Kathy Miller
Collaborators: Genentech, Inc.